Is pulmonary arterial hypertension associated with interferon-β therapy for multiple sclerosis reversible? A case study to explore the complexity

被引:1
|
作者
Anthi, Anastasia [1 ,2 ]
Stagaki, Eleni [1 ]
Rallidis, Loukianos [1 ,3 ]
Konstantonis, Dimitrios [1 ,2 ]
Evangelopoulos, Maria-Eleftheria [4 ]
Voumvourakis, Konstantinos [5 ]
Armaganidis, Apostolos [1 ,2 ]
Orfanos, Stylianos E. [1 ,2 ]
机构
[1] Attikon Hosp, Pulm Hypertens Clin, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Attikon Hosp, Dept Crit Care 2, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Attikon Hosp, Dept Cardiol 2, Athens, Greece
[4] Natl & Kapodistrian Univ Athens, Eginit Hosp, Dept Neurol, Demyelinating Dis Unit, Athens, Greece
[5] Natl & Kapodistrian Univ Athens, Attikon Hosp, Dept Neurol 2, Athens, Greece
关键词
D O I
10.1183/23120541.00328-2019
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis
    Gibbons, E.
    Promislow, S.
    Davies, R. A.
    Chandy, G.
    Stewart, D. J.
    Contreras-Dominguez, V.
    Pugliese, C.
    Dunne, R.
    Mielniczuk, L. M.
    CANADIAN RESPIRATORY JOURNAL, 2015, 22 (05) : 263 - 265
  • [2] Reversible Interferon-Induced Pulmonary Arterial Hypertension in a Patient With Multiple Sclerosis
    Garcia Ortega, Alberto
    Lopez Reyes, Raquel
    Torrents Vilar, Ana
    Zaldivar Olmeda, Enrique
    Prado Barragan, Marcos
    ARCHIVOS DE BRONCONEUMOLOGIA, 2017, 53 (10): : 596 - 597
  • [3] Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report
    Ledinek, A. H.
    Jazbec, S. S.
    Drinovec, I.
    Rot, U.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (07) : 885 - 886
  • [9] Severe pulmonary arterial hypertension associated with interferon beta 1a therapy for multiple Sclerosis: first case report
    Masmoudi, K.
    Gras-Champel, V.
    Trojette, F.
    Masson, H.
    Fry, P.
    Simonneau, G.
    Andrejak, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 105 - 105